N/A Completed N=183 Randomized Double-blind Treatment

Myopia Control With the Multi-segment Lens

Myopia

Source: ClinicalTrials.gov NCT02206217 ↗

Enrolled (actual)

183

Serious AEs

0.0%

Results posted

Jul 2019

Primary outcomePrimary: Cycloplegic Refraction Change in SER — -0.93; -0.38 Diopters (D)

Summary

The purpose of this study is to determine if the Multiple-Segment (MS) spectacle lens can slow myopia progression in Hong Kong schoolchildren. MS lens is also called Defocus Incorporated Multiple Segments (DIMS) spectacle lens

Outcome Measures

Outcome	Result	p-value
PRIMARY Cycloplegic Refraction Change in SER	-0.93; -0.38	—
SECONDARY Axial Length	0.53; 0.21	—

Eligibility Criteria

Inclusion Criteria

Age at enrolment: 8-13 year
Spherical equivalent refractions (SER): -1.00 to -5.00 Dioptres (D)
Astigmatism and anisometropia of 1.50 D or less
Spectacle corrected monocular logMAR visual acuity: 0 or better
Parents' understanding and acceptance of random allocation of grouping

Exclusion Criteria

any ocular and systemic abnormalities might affect visual functions or refractive development
prior treatment of myopic control, e.g. drugs, orthokeratology, progressive addition lenses, bifocal lenses, drugs (e.g. atropine), etc.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02206217). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.